Contact Us

Vioxx
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

What dosage were you prescribed daily?

Have any of the following side effects occurred? (Please check all that apply.)





Please further describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


F.D.A. Releases Memo on Vioxx

Nov 3, 2004 | Bloomberg News

Providing details from a report it had described broadly in August, the Food and Drug Administration published a memorandum yesterday that indicated Merck's Vioxx painkiller might have contributed to 27,785 heart attacks and deaths from 1999 through 2003.

The memo, based on a sample of patient records, concluded that people taking Vioxx were more likely to have heart attacks or die from sudden cardiac arrest than people taking a competing painkiller, Celebrex from Pfizer.

The report was part of a study that an F.D.A. researcher, Dr. David J. Graham, conducted with Kaiser Permanente. The general results of the study were reported in August.

The memo by Dr. Graham, an associate director in the F.D.A.'s office of drug safety, was dated Sept. 30, the same day that Merck announced it was pulling Vioxx from the market. Merck attributed the move to its own study indicating that patients who took Vioxx for 18 months or longer were more likely to have a stroke or heart attack than patients taking a placebo.

A Merck spokeswoman, Janet Skidmore, said yesterday that the company had not yet seen the F.D.A. study and had no immediate comment.


Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo